NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1-positive solid tumors: The phase 1/2 ARROS-1 study Meeting Abstract
| Authors: | Drilon, A.; Ou, S. H. I.; Gadgeel, S.; Johnson, M.; Spira, A.; Lopes, G.; Besse, B.; Felip, E.; van der Wekken, A. J.; Calles, A.; de Miguel, M. J.; Camidge, D. R.; Elamin, Y.; Liu, S.; Bauman, J.; Haggstrom, D.; Riley, G.; Pelish, H. E.; Zhu, V. W.; Lin, J. J. |
| Abstract Title: | NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1-positive solid tumors: The phase 1/2 ARROS-1 study |
| Meeting Title: | 2022 World Conference on Lung Cancer |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 17 |
| Issue: | 9 Suppl. |
| Meeting Dates: | 2022 Aug 6-9 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-09-01 |
| Start Page: | S416 |
| Language: | English |
| DOI: | 10.1016/j.jtho.2022.07.723 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: EP08.02-041 -- Located within section named "EP08.02 Metastatic Non-Small Cell Lung Cancer - Molecular Targeted Treatments" -- Accession Number: 159037969 -- Entry Date: In Process -- Revision Date: 20220913 -- Publication Type: Article -- Supplement Title: 2022 Supplement -- Journal Subset: Biomedical; Blind Peer Reviewed; Peer Reviewed; USA -- NLM UID: 101274235. -- Source: Cinahl |
